#TC_BioPharm
LightNews LightNews
newsen.bsky.social
TC BioPharm Achieves Major Milestone in Cancer Treatment Releasing Complete Response Data#United_Kingdom#Edinburgh#TC_BioPharm#TCB008#Gamma_Delta_T_Cells
TC BioPharm Achieves Major Milestone in Cancer Treatment Releasing Complete Response Data
TC BioPharm has reported a complete molecular response in a patient with Minimal Residual Disease after innovative gamma delta T cell therapy, marking a significant milestone.
third-news.com
June 11, 2025 at 12:46 PM
newsen.bsky.social
TC BioPharm Secures European Patent for Innovative T Cell Therapy Targeting Various Diseases#United_Kingdom#Edinburgh#TC_BioPharm#Gamma_Delta_T_Cells#Patent_Rights
TC BioPharm Secures European Patent for Innovative T Cell Therapy Targeting Various Diseases
TC BioPharm has announced the acquisition of a European patent for its advanced T cell therapies, targeting microbial, oncological, and viral diseases, enhancing their therapeutic applications.
third-news.com
April 9, 2025 at 1:17 PM
newsen.bsky.social
TC BioPharm Transitions from Nasdaq to OTC Markets Amid Company Changes#NASDAQ#United_Kingdom#Edinburgh#TC_BioPharm#OTC_Markets
TC BioPharm Transitions from Nasdaq to OTC Markets Amid Company Changes
TC BioPharm has announced its impending transition from Nasdaq to OTC Markets due to compliance issues. Despite challenges, the company is committed to advancing its innovative therapies.
third-news.com
March 21, 2025 at 2:51 PM
newsen.bsky.social
TC BioPharm Unveils Strategic Outsourcing To Streamline Operations and Boost Efficiency#United_Kingdom#Edinburgh#TC_BioPharm#T_Cell_Therapy#Bryan_Kobel
TC BioPharm Unveils Strategic Outsourcing To Streamline Operations and Boost Efficiency
In a significant strategic move, TC BioPharm announces outsourcing initiatives to reduce operational costs, transitioning to a decentralized model to enhance efficiency.
third-news.com
March 18, 2025 at 12:05 PM
newsen.bsky.social
TC BioPharm Plans Acquisition of Ophthalmic Pharma Company to Expand Glaucoma Treatment Portfolio#United_Kingdom#pharmaceuticals#Edinburgh#TC_BioPharm#glaucoma
TC BioPharm Plans Acquisition of Ophthalmic Pharma Company to Expand Glaucoma Treatment Portfolio
TC BioPharm is set to acquire an innovative pharmaceutical company specializing in FDA-approved glaucoma treatments, strengthening its market position and revenue potential.
third-news.com
March 5, 2025 at 1:41 PM
newsen.bsky.social
TC BioPharm's CEO to Share Insights on Cancer at European Forum#cancer_therapy#United_Kingdom#Edinburgh#TC_BioPharm#Bryan_Kobel
TC BioPharm's CEO to Share Insights on Cancer at European Forum
Bryan Kobel, CEO of TC BioPharm, will participate in a critical cancer panel at the European Life Sciences CEO Forum, highlighting advancements in healthcare.
third-news.com
February 20, 2025 at 1:22 PM
newsen.bsky.social
TC BioPharm Completes Cohort A in ACHIEVE Clinical Trial for TCB008 Treatment#United_Kingdom#Edinburgh#TC_BioPharm#ACHIEVE_Trial#TCB008
TC BioPharm Completes Cohort A in ACHIEVE Clinical Trial for TCB008 Treatment
TC BioPharm announces successful completion of Cohort A in the ACHIEVE clinical trial, showcasing promising results for TCB008 in treating AML.
third-news.com
February 13, 2025 at 2:00 PM
newsen.bsky.social
TC BioPharm Achieves Milestone with First Patient Dosing in ACHIEVE Trial#United_Kingdom#Edinburgh#TC_BioPharm#ACHIEVE_Trial#TCB008
TC BioPharm Achieves Milestone with First Patient Dosing in ACHIEVE Trial
TC BioPharm celebrates a key achievement in its ACHIEVE trial by administering the initial doses to a patient in Cohort B, paving the way for innovative cancer therapies.
third-news.com
February 10, 2025 at 3:17 PM
newsen.bsky.social
TC BioPharm Announces Changes in ADS Ratio to Enhance Shareholder Value#United_Kingdom#Edinburgh#ADS_Ratio#TC_BioPharm#glycolysis
TC BioPharm Announces Changes in ADS Ratio to Enhance Shareholder Value
TC BioPharm has announced an update regarding its American Depositary Shares (ADS) ratio, aiming to improve shareholder value and trading dynamics in the market.
third-news.com
February 5, 2025 at 5:09 PM
newsen.bsky.social
TC BioPharm Plans Groundbreaking Studies on H5N1 Treatment Approaches#United_Kingdom#Edinburgh#TC_BioPharm#TCB008#H5N1
TC BioPharm Plans Groundbreaking Studies on H5N1 Treatment Approaches
TC BioPharm announces intentions to initiate preclinical studies for TCB008, targeting H5N1, aimed at finding innovative treatments for the viral infection.
third-news.com
January 15, 2025 at 1:43 PM
newsen.bsky.social
TC BioPharm Announces Participation in Sequire Investor Summit 2025#USA#San_Juan#TC_BioPharm#T_Cell_Therapy#Investor_Summit
TC BioPharm Announces Participation in Sequire Investor Summit 2025
TC BioPharm will showcase its innovative T cell therapies at the Sequire Investor Summit in Puerto Rico, highlighting its clinical advancements.
third-news.com
January 13, 2025 at 1:57 PM
newsen.bsky.social
The Unstoppable Rise of TC BioPharm on Nasdaq: A New Era in Immunotherapy#NASDAQ#United_Kingdom#Immunotherapy#Edinburgh#TC_BioPharm
The Unstoppable Rise of TC BioPharm on Nasdaq: A New Era in Immunotherapy
TC BioPharm (NASDAQ: TCBP) continues to thrive in the biotech sector, trading steadily as it pioneers gamma-delta T cell therapies for cancer treatment.
third-news.com
January 6, 2025 at 6:35 PM
newsen.bsky.social
TC BioPharm Reveals Strategic Approach to Acquisitions in Cell Therapy Market#United_Kingdom#Edinburgh#TC_BioPharm#Cell_Therapy#CAR-NK
TC BioPharm Reveals Strategic Approach to Acquisitions in Cell Therapy Market
TC BioPharm outlines its ongoing acquisition strategy focusing on innovative therapies in cancer treatment, particularly in NK technologies and CAR-modified cells.
third-news.com
December 31, 2024 at 3:32 PM
newsen.bsky.social
TC BioPharm Declares 25% Stock Dividend as It Eyes Growth in 2025#Stock_Dividend#United_Kingdom#Edinburgh#TC_BioPharm#gamma-delta_T_cells
TC BioPharm Declares 25% Stock Dividend as It Eyes Growth in 2025
TC BioPharm has officially approved a 25% stock dividend for shareholders, signifying confidence in the company's financial growth in 2025.
third-news.com
December 30, 2024 at 3:31 PM
newsen.bsky.social
TC BioPharm's ACHIEVE Phase 2b Trial Completes Final Dosing for Patients#United_Kingdom#Clinical_Trial#Edinburgh#TC_BioPharm#TCB008
TC BioPharm's ACHIEVE Phase 2b Trial Completes Final Dosing for Patients
TC BioPharm announces completion of full-dose regimen in its ACHIEVE Phase 2b trial, with a strong safety profile and promising recruitment figures for 2025.
third-news.com
December 20, 2024 at 1:46 PM
newsen.bsky.social
TC BioPharm Sets Date for Shareholder Meeting to Discuss Special Dividend Approval#Dividend#Shareholders#United_Kingdom#TC_BioPharm#Buckie
TC BioPharm Sets Date for Shareholder Meeting to Discuss Special Dividend Approval
TC BioPharm announces a special meeting for shareholders to discuss a proposed dividend. Details inside about the date, amount, and more.
third-news.com
December 18, 2024 at 1:49 PM
newsen.bsky.social
TC BioPharm Collaborates with CareDx for Groundbreaking Clinical Trial in Allogeneic Cell Therapy#United_Kingdom#Edinburgh#TC_BioPharm#Achieve#CareDx
TC BioPharm Collaborates with CareDx for Groundbreaking Clinical Trial in Allogeneic Cell Therapy
TC BioPharm has partnered with CareDx to enhance the ACHIEVE clinical trial, focusing on pharmacokinetic analysis of allogeneic cell therapy for AML.
third-news.com
December 11, 2024 at 12:17 PM
newsen.bsky.social
TC BioPharm Reports Progress on ACHIEVE Clinical Trial with Promising Safety Data for Cancer Treatment#United_Kingdom#Edinburgh#TC_BioPharm#ACHIEVE_Trial#TCB008
TC BioPharm Reports Progress on ACHIEVE Clinical Trial with Promising Safety Data for Cancer Treatment
TC BioPharm provides a quarterly update on the ongoing ACHIEVE clinical trial, revealing positive safety data and plans for dose escalation of TCB008.
third-news.com
December 4, 2024 at 1:57 PM